Press release
Tendinopathy Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
(Albany, United States) As per DelveInsight's assessment, globally, Tendinopathy pipeline constitutes 5+ key companies continuously working towards developing 5+ Tendinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Tendinopathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tendinopathy Market.
The Tendinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ Tendinopathy Pipeline Report - https://www.delveinsight.com/report-store/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Tendinopathy Pipeline Report:
• Tendinopathy Companies across the globe are diligently working toward developing novel Tendinopathy treatment therapies with a considerable amount of success over the years.
• Tendinopathy companies working in the treatment market are Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomedical, Zimmer Biomet, 3M, Teikoku Pharma USA Inc., DJO Global Inc., AKSIGEn, and others, are developing therapies for the Tendinopathy treatment
• Emerging Tendinopathy therapies in the different phases of clinical trials are- secukinumab, NGI226, Heated Lidocaine and Tetracaine Patch, etoricoxib, PRP Injection with eccentric exercises, Celestone, and others are expected to have a significant impact on the Tendinopathy market in the coming years.
• In November 2022, Camber Pharmaceuticals expanded its product offerings with the introduction of Naproxen Oral Suspension, which is prescribed to treat the symptoms and conditions associated with tendonitis.
• In May 2022, CoNextions Inc., a company focused on tendon repair, reported that the first patient underwent treatment with the CoNextions TR Tendon Repair System for a zone 2 flexor tendon in the little finger shortly after receiving FDA 510(k) clearance for commercializing the device.
Tendinopathy Overview
Tendinopathy is a common condition affecting tendons, characterized by pain, stiffness, and reduced function, typically resulting from overuse or repetitive strain. It encompasses two primary stages: tendinitis, involving acute inflammation, and tendinosis, marked by chronic degeneration without significant inflammation. Common sites include the Achilles tendon, rotator cuff, patellar tendon, and lateral epicondyle (tennis elbow).
The condition arises from mechanical overloading, leading to microtears in the tendon fibers. These tears, if not repaired adequately, result in a disorganized collagen matrix, impaired healing, and reduced tensile strength. Risk factors include repetitive activities, poor biomechanics, aging, obesity, and systemic conditions such as diabetes.
Tendinopathy Symptoms vary but often include localized pain that worsens with activity, tenderness, swelling, and limited range of motion. Diagnosis is primarily clinical, supported by imaging like ultrasound or MRI for assessing structural damage.
Tendinopathy Management focuses on reducing pain, restoring function, and preventing recurrence. Initial treatment includes rest, ice, and nonsteroidal anti-inflammatory drugs (NSAIDs). Rehabilitation programs emphasize eccentric strengthening exercises to promote collagen remodeling. Advanced therapies such as platelet-rich plasma (PRP) injections, extracorporeal shock wave therapy, or tendon release surgery may be used for refractory cases. Early intervention is critical for optimal recovery and prevention of chronic disability.
Get a Free Sample PDF Report to know more about Tendinopathy Pipeline Therapeutic Assessment - https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Tendinopathy Drugs Under Different Phases of Clinical Development Include:
• secukinumab: Novartis
• NGI226: Novartis
• Heated Lidocaine and Tetracaine Patch: ZARS Pharma Inc.
• etoricoxib: Merck Sharp
• PRP Injection with eccentric exercises: Erasmus Medical Center
• Celestone: CTM Biomedical
Tendinopathy Route of Administration
Tendinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Tendinopathy Molecule Type
Tendinopathy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Tendinopathy Pipeline Therapeutics Assessment
• Tendinopathy Assessment by Product Type
• Tendinopathy By Stage and Product Type
• Tendinopathy Assessment by Route of Administration
• Tendinopathy By Stage and Route of Administration
• Tendinopathy Assessment by Molecule Type
• Tendinopathy by Stage and Molecule Type
DelveInsight's Tendinopathy Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Tendinopathy product details are provided in the report. Download the Tendinopathy pipeline report to learn more about the emerging Tendinopathy therapies - https://www.delveinsight.com/report-store/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Tendinopathy Therapeutics Market include:
Key companies developing therapies for Tendinopathy are - Zimmer Biomet, 3M, AKSIGEN, Smith+Nephew, Stryker, Colfax Corporation (DJO Global Inc.), Teikoku Pharma USA Inc., Ossur, Tynor India, Merck and Co., Inc., Almatica Pharma, Inc., Teva Pharmaceuticals, and others.
Tendinopathy Pipeline Analysis:
The Tendinopathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Tendinopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tendinopathy Treatment.
• Tendinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tendinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tendinopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Tendinopathy drugs and therapies - https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Tendinopathy Pipeline Market Drivers
• Increasing Incidence, Advancements in Diagnostics, Rising Healthcare Expenditure, Focus on Regenerative Medicine, Growing Awareness, Collaborative Efforts, are some of the important factors that are fueling the Tendinopathy Market.
Tendinopathy Pipeline Market Barriers
• However, Complex Pathophysiology, limited Treatment Options, Regulatory Challenges, High Development Costs, Competition, and other factors are creating obstacles in the Tendinopathy Market growth.
Scope of Tendinopathy Pipeline Drug Insight
• Coverage: Global
• Key Tendinopathy Companies: Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomedical, Zimmer Biomet, 3M, Teikoku Pharma USA Inc., DJO Global Inc., AKSIGEn, and others
• Key Tendinopathy Therapies: secukinumab, NGI226, Heated Lidocaine and Tetracaine Patch, etoricoxib, PRP Injection with eccentric exercises, Celestone, and others
• Tendinopathy Therapeutic Assessment: Tendinopathy current marketed and Tendinopathy emerging therapies
• Tendinopathy Market Dynamics: Tendinopathy market drivers and Tendinopathy market barriers
Request for Sample PDF Report for Tendinopathy Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/tendinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Tendinopathy Report Introduction
2. Tendinopathy Executive Summary
3. Tendinopathy Overview
4. Tendinopathy- Analytical Perspective In-depth Commercial Assessment
5. Tendinopathy Pipeline Therapeutics
6. Tendinopathy Late Stage Products (Phase II/III)
7. Tendinopathy Mid Stage Products (Phase II)
8. Tendinopathy Early Stage Products (Phase I)
9. Tendinopathy Preclinical Stage Products
10. Tendinopathy Therapeutics Assessment
11. Tendinopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Tendinopathy Key Companies
14. Tendinopathy Key Products
15. Tendinopathy Unmet Needs
16 . Tendinopathy Market Drivers and Barriers
17. Tendinopathy Future Perspectives and Conclusion
18. Tendinopathy Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/sample-request/acute-intermittent-porphyria-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Astigmatism Market: https://www.delveinsight.com/report-store/astigmatism-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Colorectal Cancer Crc Market: https://www.delveinsight.com/report-store/colorectal-cancer-crc-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Balloon Catheters Market Market: https://www.delveinsight.com/report-store/balloon-catheters-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Cardiac Biomarkers Testing Devices Market: https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market-insight
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Adamantinoma Market: https://www.delveinsight.com/report-store/adamantinoma-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tendinopathy Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3807972 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Tendinopathy
Tendinopathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tendinopathy pipeline constitutes 5+ key companies continuously working towards developing 5+ Tendinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tendinopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tendinopathy Market.
The Tendinopathy Pipeline report embraces in-depth…
Tendinopathy Market Outlook: Growth Driven by Sports Injuries, Biologics & Advan …
The Global Tendinopathy Market reached US$ 215.26 billion in 2023 and is expected to reach US$ 299.16 billion by 2031 growing with a CAGR of 4.2% during the forecast period 2024-2031.
The tendinopathy market focuses on the diagnosis, treatment, and management of tendinopathy, a condition characterized by pain, swelling, and impaired tendon function caused by overuse, injury, or degeneration. Common types include Achilles, rotator cuff, patellar, and lateral epicondylitis…
Tendinopathy Market Size, Share and Competitive Landscape
Tendinopathy refers to the condition where the tendons, which are the thick fibrous tissues that connect muscles to bones, become damaged or inflamed, leading to pain, swelling, and restricted movement. It is a common issue for athletes, manual laborers, and aging populations. The tendinopathy market is growing rapidly, driven by the rising incidence of sports injuries, increasing healthcare access, and advancements in treatments, including biologics, physical therapy, and surgical interventions.…
Tendinopathy Market is expected to reach US$ 299.16 billion by 2031- Zimmer Biom …
The Tendinopathy Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/tendinopathy-market
What is the projected growth…
Tendinopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, E …
(Albany, USA) The Tendinopathy market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as MiMedx Group, Novartis Pharmaceuticals, Ipsen, Orthocell Limited, ZARS Pharma Inc., Zimmer Biomet, Causeway Therapeutics, Travanti Pharma Inc., Abbisko Therapeutics Co, Ltd, Deciphera Pharmaceuticals, LLC, Daiichi Sankyo, AmMax Bio, Inc., AmMax Bio, Inc.,
DelveInsight's "Tendinopathy Market Insights, Epidemiology, and Market Forecast 2034."…
Tendinopathy Market Forecasted for Substantial Growth (2024-2031) | Zimmer Biome …
The Tendinopathy Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Get a Free Sample PDF - https://datamintelligence.com/download-sample/tendinopathy-market
What is the projected growth rate (CAGR) of the Global Tendinopathy market from 2024…
